Walleye Capital’s Edgewise Therapeutics EWTX Stock Holding History

Walleye Capital’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-700	Closed	-$9.18K	–	4659
2025 Q2	$9.18K	Buy	+700	New	+$10.1K	﹤0.01%	4315

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Walleye Capital's EWTX Position: Q3 2025 in Review

Walleye Capital sold out of Edgewise Therapeutics (EWTX) in Q3 2025, closing a stake of 86,882 shares — an estimated $1.14M sold.

Walleye Capital first reported a position in EWTX in Q1 2022 and held it in 6 quarters. The position peaked at $6.47M in Q3 2024. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

Walleye Capital reported no remaining Edgewise Therapeutics position as of Q3 2025 after selling out during the quarter.
Walleye Capital sold 86,882 Edgewise Therapeutics shares in Q3 2025, an estimated $1.14M.
Walleye Capital first reported a position in Edgewise Therapeutics in Q1 2022 and held it in 6 quarters.
Walleye Capital's Edgewise Therapeutics position peaked at $6.47M in Q3 2024.
173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.